Study finds adolescent girls and young women in Africa will use HIV prevention products
Interim results of the REACH study of daily oral PrEP and monthly dapivirine vaginal ring presented at IAS 2021 - the 11th IAS Conference on HIV Science
Published 2021-07-15 · Original archive entry · Explore research explainers
Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada® as oral pre-exposure prophylaxis (PrEP) and the monthly END